196 related articles for article (PubMed ID: 27618729)
1. Patient-provider communication and hormonal therapy side effects in breast cancer survivors.
Lin JJ; Chao J; Bickell NA; Wisnivesky JP
Women Health; 2017 Sep; 57(8):976-989. PubMed ID: 27618729
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
Nyrop KA; Callahan LF; Rini C; Altpeter M; Hackney B; DePue A; Wilson A; Schechter A; Muss HB
Support Care Cancer; 2016 Jun; 24(6):2643-50. PubMed ID: 26757739
[TBL] [Abstract][Full Text] [Related]
3. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
4. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
5. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; MacDonald R; Wood B; Rushovich E; Helzlsouer KJ
Climacteric; 2012 Aug; 15(4):339-49. PubMed ID: 22191462
[TBL] [Abstract][Full Text] [Related]
6. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
7. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Paranjpe R; John G; Trivedi M; Abughosh S
Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
[TBL] [Abstract][Full Text] [Related]
8. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.
Liu Y; Malin JL; Diamant AL; Thind A; Maly RC
Breast Cancer Res Treat; 2013 Feb; 137(3):829-36. PubMed ID: 23263740
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy toxicity: management options.
Henry NL
Am Soc Clin Oncol Educ Book; 2014; ():e25-30. PubMed ID: 24857109
[TBL] [Abstract][Full Text] [Related]
11. [Aromatase inhibitors and arthralgia].
Nagykálnai T; Landherr L; Mészáros E
Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal treatment of breast cancer. Implications for quality of life, communication and improved therapy].
Denton S
Oncologica; 1996 Feb; 13(1):18-20. PubMed ID: 9516751
[No Abstract] [Full Text] [Related]
13. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
14. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
15. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.
Berkowitz MJ; Thompson CK; Zibecchi LT; Lee MK; Streja E; Berkowitz JS; Wenziger CM; Baker JL; DiNome ML; Attai DJ
J Cancer Surviv; 2021 Feb; 15(1):29-39. PubMed ID: 32804353
[TBL] [Abstract][Full Text] [Related]
16. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.
Fleming L; Agnew S; Peddie N; Crawford M; Dixon D; MacPherson I
Breast; 2022 Aug; 64():63-84. PubMed ID: 35609380
[TBL] [Abstract][Full Text] [Related]
17. Online discussion of drug side effects and discontinuation among breast cancer survivors.
Mao JJ; Chung A; Benton A; Hill S; Ungar L; Leonard CE; Hennessy S; Holmes JH
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):256-62. PubMed ID: 23322591
[TBL] [Abstract][Full Text] [Related]
18. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study.
Nestoriuc Y; von Blanckenburg P; Schuricht F; Barsky AJ; Hadji P; Albert US; Rief W
Ann Oncol; 2016 Oct; 27(10):1909-15. PubMed ID: 27551051
[TBL] [Abstract][Full Text] [Related]
19. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
20. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
